Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- cedazuridine / decitabine
- talimogene laherparepvec
Interactions between your drugs
decitabine talimogene laherparepvec
Applies to: cedazuridine / decitabine, talimogene laherparepvec
CONTRAINDICATED: Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.
MANAGEMENT: Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.
References (1)
- (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
Drug and food interactions
cedazuridine food
Applies to: cedazuridine / decitabine
ADJUST DOSING INTERVAL: There are no data regarding the concurrent administration of oral cedazuridine-decitabine with food.
MANAGEMENT: The manufacturer recommends that patients avoid eating for 2 hours before and 2 hours after administration of oral cedazuridine-decitabine.
References (1)
- (2020) "Product Information. Inqovi (cedazuridine-decitabine)." Taiho Oncology, Inc.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Reblozyl
Reblozyl is used to treat anemia in adults with beta-thalassemia or myelodysplastic syndromes ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Dacogen
Dacogen (decitabine) is used to treat myelodysplastic syndromes (certain types of blood or bone ...
Inqovi
Inqovi (decitabine and cedazuridine) is used for the treatment of myelodysplastic syndromes (MDS) ...
Rytelo
Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.